ValiRx (VAL) Share Price, News & Analysis

Company Overview

ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.

Key Stats

• Today's Range: 0.51 to 0.59
• 50-Day Range: 0.40 to 0.62
• 52-Week Range: 0.38 to 3.50
• Volume: 358,243 shs
• Average Volume: 5.64 million shs
• Market Capitalization: £1.92 million
• P/E Ratio: N/A
• Dividend Yield: 0.63%
• Price Target: N/A
• Consensus Rating: N/A

VAL Stock Analysis - Frequently Asked Questions

How have VAL shares performed this year?

ValiRx's stock was trading at GBX 0.65 at the beginning of the year. Since then, VAL stock has decreased by 22.0% and is now trading at GBX 0.51.
View the best growth stocks for 2025 here.

How were ValiRx's earnings last quarter?

ValiRx plc (LON:VAL) announced its quarterly earnings data on Monday, September, 7th. The company reported ($4.43) earnings per share (EPS) for the quarter. ValiRx had a negative net margin of 20,554.01% and a negative trailing twelve-month return on equity of 55.84%.

How do I buy shares of ValiRx?

Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Lloyds Banking Group (LLOY), IQE (IQE) and Scirocco Energy Plc (SOLO.L) (SOLO).

Company Calendar

• Last Earnings: 9/07/2020
• Today: 5/27/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Petroleum And Natural Gas
• Current Symbol: LON:VAL
• CIK: N/A
• Web: www.valirx.com
• Phone: +44-20-30084416
• Fax: N/A
• Employees: 5,450
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-5,709,352.91
• Net Margins: -20,554.01%
• Pretax Margin: N/A
• Return on Equity: -55.84%
• Return on Assets: -35.98%

Debt

• Debt-to-Equity Ratio: 0.44
• Current Ratio: 6.65
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: £27,777.32
• Price / Sales: 69.29
• Cash Flow: GBX 0.01 per share
• Price / Cash Flow: 62.50
• Book Value: GBX 2.67 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 379,605,148
• Free Float: N/A
• Market Cap: £1.92 million
• Optionable: Not Optionable
• Beta: 0.59